Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEP 010 - PEP-Therapy

Next Previous
Search
Drug Profile

PEP 010 - PEP-Therapy

Alternative Names: DPT C9h; PEP-010

Latest Information Update: 01 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PEP-Therapy
  • Developer Curie Institute; PEP-Therapy
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action Caspase 9 inhibitors; Protein phosphatase 2A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Ovarian cancer; Triple negative breast cancer

Most Recent Events

  • 01 Apr 2025 Phase I development is ongoing in Solid tumours (Combination therapy, Monotherapy, Metastatic disease, Recurrent) in France (IV-infusion, Injection) (NCT04733027)
  • 03 Mar 2025 PEP 010 - PEP-Therapy receives Orphan Drug status for Pancreatic cancer in USA
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Metastatic disease, Recurrent) in France (IV-infusion, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top